Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Alemtuzumab × Clear all

Phase

Status

Completed 84 Terminated 34 Unknown 12 Withdrawn 4 Active not recruiting 3 Suspended 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 1

Interventions

Cisplatin 112 Carboplatin 110 Drug Therapy 108 Oxaliplatin 97 Bevacizumab 90 Capecitabine 89 Paclitaxel 82 Radiotherapy 80 Gemcitabine 78 Cyclophosphamide 78 pembrolizumab 77 tislelizumab 75 Specimen Handling 63 Fluorouracil 59 toripalimab 58 Docetaxel 54 Injections 52 sintilimab 51 Magnetic Resonance Spectroscopy 51 Surgical Procedures, Operative 50 130-nm albumin-bound paclitaxel 45 Biopsy 42 Leucovorin 41 fludarabine 38 Standard of Care 38 Pemetrexed 38 Immune Checkpoint Inhibitors 38 anlotinib 37 Radiosurgery 37 lenvatinib 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06084780 2026-01-23

TRANSCAPE

Case Comprehensive Cancer Center

Phase 2 Not yet recruiting

Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon ⚡